Related Experiment Video

Updated: Sep 23, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

[A comparison between diltiazem SR and diltiazem HCL in the treatment of angina pectoris]

X S Yang1, Q L Li, K Rong

  • 1Department of Cardiology, Great Wall Hospital, Beijing.

Zhonghua Nei Ke Za Zhi
|January 1, 1993
PubMed

Insights

This study compared diltiazem sustained-release (SR) and diltiazem hydrochloride (HCL) for angina pectoris treatment. Both formulations showed similar efficacy and safety, with diltiazem SR offering greater convenience due to twice-daily dosing.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Angina pectoris is a common cardiovascular condition requiring effective management.
  • Diltiazem is a calcium channel blocker used in treating angina.
  • Comparing different diltiazem formulations is crucial for optimizing patient care.

Purpose of the Study:

  • To compare the clinical efficacy and safety of diltiazem sustained-release (SR) versus diltiazem hydrochloride (HCL) in patients with angina pectoris.
  • To evaluate the convenience of diltiazem SR compared to diltiazem HCL.

Main Methods:

  • A clinical study involving 168 patients diagnosed with angina pectoris.
  • Patients were randomized into two groups: diltiazem SR (n=88) and diltiazem HCL (n=80).
  • Demographic data and coronary heart disease duration were comparable between groups.

Main Results:

  • Diltiazem SR demonstrated a slightly higher total clinical effect (94.3%) compared to diltiazem HCL (82.5%).
  • Electrocardiogram (ECG) improvement rates were similar: 53.3% for diltiazem SR and 53.4% for diltiazem HCL.
  • Adverse effect rates were comparable: 12.5% for diltiazem SR and 14.4% for diltiazem HCL.

Conclusions:

  • Both diltiazem SR and diltiazem HCL exhibit similar therapeutic effects and safety profiles for angina pectoris.
  • Diltiazem SR offers improved patient convenience due to a less frequent dosing schedule (twice daily).
  • The findings support diltiazem SR as a viable and convenient option for managing angina pectoris.

More Related Videos

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina II: Classification01:27

Angina II: Classification

Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...